Moderna gains as FDA backtracks and accepts flu shot for review
Source: SeekingAlpha
2026-02-18 07:50:16 ET
More on Moderna
- Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript
- Moderna, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Moderna: FDA RTF Derails mRNA-1010 And Reignites The Sell Case
- Changes to U.S. vaccine policy under RFK Jr. challenged in court
- Earnings Scorecard: Healthcare sector shows strong top-line pulse
Read the full article on Seeking Alpha
For further details see:
Moderna gains as FDA backtracks and accepts flu shot for review
Moderna Inc.
NASDAQ: MRNA
MRNA Trading
-2.15% G/L:
$52.70 Last:
3,132,625 Volume:
$53.18 Open:
MRNA Latest News
MRNA Stock Data
$16,877,354,918
348,095,445
0.39%
298
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
